๐Ÿ“ก TrialPulse
RECRUITINGPHASE1 / PHASE2

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

NCT07631325ยทJohn Kirkwoodยทsource: ClinicalTrials.gov โ†—ยทupdated 2026-10-19
Registry history
Events detected for this trial โ€” severity ร— confidence ร— recency
Neon
How to read the confidence score: 1.0 = observed โ€” the registry record itself changed (a fact). <1.0 (e.g. 0.7) = signal โ€” inferred by a heuristic rule from the data; it flags something worth a look, it is not a confirmed finding. Values below are shown raw from the database; the highlighted parts are the actual values, dimmed parts are JSON syntax.
trial seenhigh2026-10-19
null โ†’ {"status":"RECRUITING","last_update_posted_at":"2026-10-19"}
Key dates
Start2026-11-30
Primary completion2028-07-31
Enrollment28estimated
Unresectable Cutaneous MelanomaDRUG
Site map
Per-site markers colored by site status
Live map
recruitingUPMC Hillman Cancer CenterPittsburgh, United States